These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21470371)

  • 21. [Detection of multiple myeloma cells using multicolor immunofluorescence and flow cytometry].
    Tousková M; Maisnar V; Krejsek J; Kopecký O
    Vnitr Lek; 1999 Dec; 45(12):708-12. PubMed ID: 10951845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
    Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
    Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
    Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
    Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
    Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
    Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
    Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
    Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters.
    Gupta S; Karandikar NJ; Ginader T; Bellizzi AM; Holman CJ
    Cytometry B Clin Cytom; 2018 May; 94(3):500-508. PubMed ID: 29316245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
    Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
    Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunophenotypic characterization of normal and abnormal plasma cells in bone marrow of newly diagnosed multiple myeloma patients.
    Awasthi NP; Mishra S; Gupta G; Kumari S; Bajpayee A; Singh P; Husain N
    Indian J Pathol Microbiol; 2023; 66(2):295-300. PubMed ID: 37077071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model.
    Cannizzo E; Carulli G; Del Vecchio L; Ottaviano V; Bellio E; Zenari E; Azzarà A; Petrini M; Preffer F
    Am J Clin Pathol; 2012 Mar; 137(3):377-86. PubMed ID: 22338049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistological analysis in diagnosis of plasma cell myeloma based on cytoplasmic kappa/lambda ratio of CD38-positive plasma cells.
    Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Nishiwaki U; Masuda Y; Hiraoka N; Takayama A; Nishimura Y; Tsuji M; Hanafusa T
    Hematology; 2012 Nov; 17(6):317-20. PubMed ID: 23168070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.
    Paiva B; Almeida J; Pérez-Andrés M; Mateo G; López A; Rasillo A; Vídriales MB; López-Berges MC; Miguel JF; Orfao A
    Cytometry B Clin Cytom; 2010 Jul; 78(4):239-52. PubMed ID: 20155853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
    Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
    Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigenic transformation in plasma cell dyscrasia.
    Cruse JM; Lewis RE; Webb RN; Sanders CM; Tillman BF; Beason K; Lam J; Koehler J
    Exp Mol Pathol; 2006 Oct; 81(2):157-61. PubMed ID: 16908019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma cells in peripheral blood stem cell harvests from patients with multiple myeloma are predominantly polyclonal.
    Pope B; Brown R; Gibson J; Joshua D
    Bone Marrow Transplant; 1997 Aug; 20(3):205-10. PubMed ID: 9257888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.
    Hu Y; Wang M; Chen Y; Chen X; Fang F; Liu S; Zhang Y; Wu X; Zhu P
    Chin Med J (Engl); 2014; 127(15):2765-70. PubMed ID: 25146610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
    Kimlinger T; Witzig TE
    Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.
    Zhao X; Huang Q; Slovak M; Weiss L
    Am J Clin Pathol; 2006 Jun; 125(6):895-904. PubMed ID: 16690489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.